DUBAI: The Emirates Drug Establishment (EDE) has announced a sweeping reduction in the retail prices of 168 pharmaceutical products, slashing the costs of critical and chronic disease medications by up to 60 per cent. The revised pricing framework officially comes into effect across all UAE pharmacies on May 30, significantly lowering the financial burden on patients managing long-term health conditions.
The strategic price drop targets high-cost biologic and vital medicines prescribed for cardiovascular diseases, diabetes, hypertension, oncology, and neurological disorders. Discounts range from approximately 5 per cent to nearly 60 per cent depending on the therapeutic category. Pharmacies nationwide are actively updating their digital billing systems to reflect the newly mandated consumer rates.
Table of Contents
Major Price Reductions on UAE Cardiovascular and Cancer Medications
The highest percentage reductions apply to critical care and oncology sectors, directly addressing some of the most capital-intensive treatments in the domestic healthcare market. Cardiovascular diseases remain the leading cause of mortality in the United Arab Emirates, accounting for up to 40 per cent of all deaths nationwide. To combat this, the EDE has unified the pricing for all doses of the cholesterol-lowering drug Zocor (Simvastatin), which recorded a drastic 59.5 per cent reduction.
Advanced oncology medications also witnessed substantial financial relief. The price of Alunbrig 180 mg, prescribed for advanced lung cancer, fell from Dh26,433 to Dh21,108. The lower 90 mg and 30 mg dosages of Alunbrig dropped to Dh12,520 and Dh4,173 respectively. Xeloda 150 mg, heavily utilised in breast, colon, and rectal cancer treatments, was reduced from Dh347 to Dh241, representing one of the most significant monetary drops within the broader therapeutic category.
Sweeping Discounts for Diabetes and Hypertension Prescriptions
The latest government regulatory decree introduces vital cost savings for patients requiring daily management of Type 2 diabetes and severe hypertension. Blood pressure medications saw major retail reductions, with Aprovel 300 mg declining from Dh117 to Dh85, while the widely prescribed Renitec 20 mg dropped from Dh83 to Dh62. Additional hypertension treatments like Lercadip 20 mg decreased from Dh98 to Dh89, and SEVIKAR 20/5 mg declined from Dh112 to Dh93.
Blood thinners crucial for stroke prevention and post-surgical recovery were concurrently adjusted, bringing Pradaxa 150 mg down from Dh438.50 to Dh394.50. Diabetes care regimens will now be considerably more affordable for residents and expatriates alike. The Type 2 diabetes medication Amaryl 3 mg has been reduced from Dh57.50 to Dh47.50, and its 1 mg counterpart will now retail at Dh19 instead of Dh25.
Regulating EDE Prices for Psychiatric and Specialised Healthcare Treatments
Treatments for psychological and neurological disorders were also heavily regulated under the new federal directives. Invega (Paliperidone), an extended-release treatment for schizophrenia, saw its 6 mg dosage consumer price fall sharply from Dh562 to Dh381.50. The 9 mg dosage of Invega witnessed an even larger reduction, dropping from Dh843 to Dh416.
Ophthalmic treatments followed a similar downward trajectory, with the glaucoma medication Xalatan slashed by 51.7 per cent. Advanced therapies for chronic heart failure were also addressed, with Verquvo 10mg dropping from Dh499.50 to Dh474.50. While the EDE has officially confirmed the specific pricing adjustments for these major medications, federal authorities have not yet published the exhaustive public catalogue detailing every single minor dosage variation among the 168 pharmaceutical products.
Strategic Healthcare Reforms Driving UAE Medication Affordability
These comprehensive price reforms build upon the structural market shifts initiated by Federal Decree-Law No. (38) of 2024 Governing Medical Products. That earlier legislation fundamentally disrupted the single-agent medical distribution monopoly, forcing international pharmaceutical manufacturers to register multiple authorised agents across the Emirates.
The legislative move was specifically designed to enhance supply chain resilience and eradicate monopolistic pricing structures. EDE officials confirmed the dual strategy of breaking import monopolies and mandating retail price caps secures a continuous, affordable supply of essential medications during periods of high clinical demand.
